Advertisement

Breast Cancer pp 325-342 | Cite as

Immunotherapy and Gene Therapy for Breast Cancer

  • Daniela Santoli
  • Sophie Visonneau
Chapter
Part of the Current Clinical Oncology book series (CCO)

Abstract

To this day, surgery, chemotherapy, hormonal therapy, and radiation therapy remain the main forms of treatment for breast cancer. Although these approaches reduce the risk of death and can induce complete remissions in most patients, many tumors will recur as metastatic lesions. In recent years, novel therapies have been developed that work independently or in conjunction with conventional treatments to minimize side effects and enhance therapeutic efficacy. At least two areas have emerged in which the biology of breast cancer is most likely to have a therapeutic impact. The first area involves growth factors and their receptors, the second revolves around neoangiogenesis. In addition, cell- and gene-based approaches are being evaluated in the clinic that have either a direct tumoricidal function or act by stimulating the immune system against the patient’s own tumor cells. This chapter reviews the current status of these new therapies and some of the new products that are being evaluated for clinical toxicity and preliminary efficacy.

Keywords

Breast Cancer Gene Therapy Metastatic Breast Cancer Allogeneic Bone Marrow Transplantation Keyhole Limpet Hemocyanin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kihara A, Pastan I (1995) Cytotoxic activity of chimeric toxins containing the epidermal growth factor-like domain of heregulins fused to PE38KDEL, a truncated recombinant form of Pseudomonas exotoxin. Cancer Res. 55, 71–77.Google Scholar
  2. 2.
    Valone FH, Kaufman PA, Guyre PM, et al. (1995) Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpress the protooncogene HER-2/neu. J. Clin. Oncol. 13, 2281–2292.PubMedGoogle Scholar
  3. 3.
    Zhang L, Chang C, Bacus SS, et al. (1995) Suppressed transformation and induced differentiation of HER2/neu-overexpressing breast cancer cells by emodin. Cancer Res. 55, 3890–3896.PubMedGoogle Scholar
  4. 4.
    Baselga J, Tripathy D, Mendelsohn J, et al. (1995) Phase II study of recombinant human anti-HER2 monoclonal antibody (rhu-Mab HER2) in stage IV breast cancer: HER2-shedding dependent pharmacokinetics and antitumor activity. Proc. Am. Soc. Clin. Oncol. 14, 103.Google Scholar
  5. 5.
    Pegram M, Lipton A, Pietras R, et al. (1995) Phase II study of intravenous recombinant humanized anti-p185 HER-2 monoclonal antibody (rhuMab HER-2) plus cisplatin in patients with HER-2/neu overexpressing metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 14, 106.Google Scholar
  6. 6.
    Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82, 4–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Kim KJ, Li B, Winer J, et al. (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841–844.PubMedCrossRefGoogle Scholar
  8. 8.
    Kusaka M, Sudo K, Matsutani E, et al. (1994) Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br. J. Cancer 69, 212–216.PubMedCrossRefGoogle Scholar
  9. 9.
    Taraboletti G, Garofalo A, Belotti D, et al. (1995) Inhibition of angiogenesis and murine hemangioma growth by Batimastat, a synthetic inhibitor of matrix metalloproteinases. J. Natl. Cancer Inst. 87, 293–298.PubMedCrossRefGoogle Scholar
  10. 10.
    Guerin C, Laterra J, Masnyk T, et al. (1992) Selective endothelial growth inhibition by tetracyclines that inhibit collagenase. Biochem. Biophys. Res. Commun. 188, 740–745.PubMedCrossRefGoogle Scholar
  11. 11.
    Brooks PC, Clark RAF, and Cheresh DA (1994) Requirement of vascular integrin av133 for angiogenesis. Science 264, 569–571.PubMedCrossRefGoogle Scholar
  12. 12.
    Boxhorn HKE, Eck SL (1998) Gene therapy for breast cancer. Hematal. Oncol. Clin. North Am. 12, 665–675.CrossRefGoogle Scholar
  13. 13.
    Nielsen LL, Dell J, Maxwell E, et al. (1997) Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. Cancer Gene Ther. 4, 129–138.PubMedGoogle Scholar
  14. 14.
    Nielsen LL, Gurnani M, Syed J, et al. (1998) Recombinant El-deleted adenovirus-mediated gene therapy for cancer: efficacy studies with p53 tumor suppressor gene and liver histology in tumor xenograft models. Hum. Gene Ther. 9, 681–694.PubMedCrossRefGoogle Scholar
  15. 15.
    Raper SE, Haskal ZJ, Ye X, et al. (1998) Selective gene transfer into the liver of non-human primates with El deleted, E2A-defective, or El-E4 deleted recombinant adenoviruses. Hum. Gene Ther. 9, 671–679.PubMedCrossRefGoogle Scholar
  16. 16.
    Li Z, Shanmugam N, Katayose D, et al. (1997) Enzyme/prodrug gene therapy approach for breast cancer using a recombinant adenovirus expressing Escherichia coli cytosine deaminase. Cancer Gene Ther. 4, 113–117.PubMedGoogle Scholar
  17. 17.
    Putzer BM, Bramson JL, Addison CL, et al. (1998) Combination therapy with interleukin-2 and wild-type p53 expressed by adenoviral vectors potentiates tumor regression in a murine model of breast cancer. Hum. Gene Ther. 9, 707–718.PubMedCrossRefGoogle Scholar
  18. 18.
    Topalian SL, Solomon D, Avis FP, et al. (1988) Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J. Clin. Oncol. 6, 839–853.PubMedGoogle Scholar
  19. 19.
    Hoover JC, Hanna MG Jr (1991) Immunotherapy by active specific immunization. In: ( DeVita VT, Hellman S, Rosenberg SA (eds.) Biological Therapy of Cancer. JB Lippincott, Philadelphia, p. 670.Google Scholar
  20. 20.
    Elder EM, Lotze MT, and Whiteside TL (1996) Successful culture and selection of cytokine gene-modified human dermal fibroblasts for the biologic therapy of patients with cancer. Hum. Gene Ther. 7, 479–487.PubMedCrossRefGoogle Scholar
  21. 21.
    Weitzman MD, Wilson JM, Eck SL (1995) Adenovirus vectors in cancer gene therapy. In: Sobol RE, Scanlon KJ (eds.) The Internet Book of Gene Therapy: Cancer. Appleton & Lange, Stamford CT, p. 17.Google Scholar
  22. 22.
    Marc RA, Addison CL, Snider D, et al. (1997) Tumour immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNF alpha. Gene Ther. 4, 1181–1188.CrossRefGoogle Scholar
  23. 23.
    Zhang JF, Hu C, Geng Y, et al. (1996) Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy. Proc. Natl. Acad. Sci. USA 93, 4513–4518.PubMedCrossRefGoogle Scholar
  24. 24.
    Hareuveni M, Gautier C, Kieny MP, et al. (1990) Vaccination against tumor cells expressing breast cancer epithelial tumor antigen. Proc. Natl. Acad. Sci. USA 87, 9498–9502.PubMedCrossRefGoogle Scholar
  25. 25.
    Bu D, Domenech N, Lewis J, et al. (1993) Recombinant vaccinia mucin vector: in vitro analysis of expression of tumor-associated epitopes for antibody and human cytotoxic T cell recognition. J. Immunother. 14, 127–135.CrossRefGoogle Scholar
  26. 26.
    Ding L, Lalani EN, Reddish M, et al. (1993) Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene. Cancer Immunol. Immunother. 36, 9–17.PubMedCrossRefGoogle Scholar
  27. 27.
    Pastan I, Gottesman MM (1991) Multidrug resistance. Annu. Rev. Med. 42, 277–286.PubMedCrossRefGoogle Scholar
  28. 28.
    Hanania EG, Fu S, Roninson I, et al. (1995) Resistance to taxol chemotherapy produced in mouse marrow cells by safety-modified retroviruses containing a human MDR-1 transcription unit. Gene Ther. 2, 1–6.Google Scholar
  29. 29.
    Rosenberg S, Lotze M, Muul L, et al. (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 aone. N. Engl. J. Med. 316, 889–897.PubMedCrossRefGoogle Scholar
  30. 30.
    Law T, Motzer R, Mazumdar M, et al. (1995) Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell cancer. Cancer 76, 824–832.PubMedCrossRefGoogle Scholar
  31. 31.
    Wei W-Z, Heppner G (1996) Breast cancer immunology. Cancer Treat. Res. 83, 395–410.PubMedCrossRefGoogle Scholar
  32. 32.
    Coventry B, Weeks S, Heckford S, et al. (1996) Lack of IL-2 cytokine expression despite IL-2 messenger mRNA transcription in tumor-infiltrating lymphocytes in primary breast carcinoma: selective expression of early activation markers. J. Immunol. 156, 3486–3492.PubMedGoogle Scholar
  33. 33.
    Becker J, Czerny C, Brocker E (1994) Maintenance of clonal anergy by endogenously produced IL-10. Int. Immunol. 6, 1605–1612.PubMedCrossRefGoogle Scholar
  34. 34.
    Beissert S, Hosoi J, Grabbe S, et al. (1995) IL-10 inhibits tumor antigen presentation by epidermal antigen-presenting cells. J. Immunol. 154, 1280–1286.PubMedGoogle Scholar
  35. 35.
    Sparano JA, Fisher RI, Weiss GR, et al. (1994) Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors. J. Immunother. 16, 216–223.CrossRefGoogle Scholar
  36. 36.
    Horowitz M, Gale R, Sondel P, et al. (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75, 555–562.PubMedGoogle Scholar
  37. 37.
    Porter D, Antin J (1997) Graft-versus-leukemia effect of allogeneic bone marrow transplantation and donor mononuclear cell infusions. In: Winter J (ed.) Blood Stem Cell Transplantation Kluwer, Norwell, MA, pp. 57–86.CrossRefGoogle Scholar
  38. 38.
    Collins R, Shpilberg O, Drobyski W, et al. (1997) Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Oncol. 15, 433–444.PubMedGoogle Scholar
  39. 39.
    Porter D, Connors J, VanDeerlin V, et al. (1999) Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. J. Clin. Oncol. 17, 1234–1243.PubMedGoogle Scholar
  40. 40.
    Giralt S, Estey E, Albitar M, et al. (1997) Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89, 4531–4536.PubMedGoogle Scholar
  41. 41.
    Khouri I, Keating M, Korbling M, et al. (1988) Transplant-lite: induction of graft-vs-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J. Clin. Oncol. 16, 2817–2824.Google Scholar
  42. 42.
    Ueno N, Rondon G, Mirza N, et al. (1998) Allogeneic peripheral blood progenitor cell transplantation for poor risk patients with metastatic breast cancer. J. Clin. Oncol. 16, 986–993.PubMedGoogle Scholar
  43. 43.
    Eibl B, Schwaighofer H, Nachbauer D, et al. (1996) Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 88, 1501–1508.PubMedGoogle Scholar
  44. 44.
    Or R, Ackerstein A, Nagler A, et al. (1998) Allogeneic cell-mediated immunotherapy for breast cancer after autologous stem cell transplantation: a clinical pilot study. Cyto. Cell. Mol. Thez 4, 1–6.Google Scholar
  45. 45.
    O’Connor R, Cesano A, Lange B, et al. (1991) Growth factor requirements of childhood acute T lymphoblastic leukemia: correlation between presence of chromosomal abnormalities and ability to grow permanently in vitro. Blood 77, 1534–1545.PubMedGoogle Scholar
  46. 46.
    Cesano A, Visonneau S, Cioé L, Clark SC, Rovera G, and Santoli D (1994) Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach. J. Clin. Invest. 94, 1076–1084.PubMedCrossRefGoogle Scholar
  47. 47.
    Cesano A, Visonneau S, and Santoli D (1995) Treatment of experimental glioblastoma with a human MHC non-restricted cytotoxic T-cell line. Cancer Res. 55, 96–101.PubMedGoogle Scholar
  48. 48.
    Cesano A, Visonneau S, Cioé L, Clark SC, Santoli D (1995) Effects of lethal irradiation and cyclosporin A treatment on the growth and tumoricidal activity of a T cell clone potentially useful in cancer therapy. Cancer Immunol. Immunother. 40, 139–151.PubMedCrossRefGoogle Scholar
  49. 49.
    Cesano A, Visonneau S, Jeglum KA, et al. (1996) Phase I clinical trial with a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in dogs with advanced tumors. Cancer Res. 56, 3021–3029.PubMedGoogle Scholar
  50. 50.
    Cesano A, Visonneau S, Pasquini S, Rovera G, Santoli D (1996) Anti-tumor efficacy of a human MHC nonrestricted cytotoxic T cell line (TALL-104) in immunocompetent mice bearing syngeneic leukemia. Cancer Res. 56, 4444–4452.PubMedGoogle Scholar
  51. 51.
    Visonneau S, Cesano A, Torosian M, Santoli D (1997) Cell therapy of a highly invasive human breast carcinoma implanted in immunodeficient (SCID) mice. Clin. Cancer Res. 3, 1491–1500.PubMedGoogle Scholar
  52. 52.
    Visonneau S, Cesano A, Tran T, Jeglum KA, Santoli D (1997) Successful treatment of canine malignant histiocytosis with the human MHC non-restricted cytotoxic T cell line TALL-104. Clin. Cancer Res. 3, 1789–1797.PubMedGoogle Scholar
  53. 53.
    Cesano A, Visonneau S, Santoli D (1998) TALL-104 cell therapy of human solid tumors implanted in immunodeficient (SCID) mice. Anticancer Res. 18, 2289–2295.PubMedGoogle Scholar
  54. 54.
    Cesano A, Visonneau S, Tran T, Santoli D (1999) Biodistribution of human MHC non-restricted TALL-104 killer cells in healthy and tumor bearing mice. Int. J. Oncol. 4, 245–251.Google Scholar
  55. 55.
    Visonneau S, Cesano A, Jeglum KA, Santoli D (1999) Adjuvant treatment of canine osteosarcoma with the human cytotoxic T cell line TALL-104. Clin. Cancer Res. 5, 1868–1875.PubMedGoogle Scholar
  56. 56.
    Visonneau S, Cesano A, Porter DL, et al. (2000) Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer. Clin. Cancer Res. 6, 1744–1754.PubMedGoogle Scholar
  57. 57.
    Visonneau S, Cesano A, Jeglum KA, Santoli D (1999) Adoptive therapy of canine metastatic mammary carcinoma with the human MHC non-restricted cytotoxic T-cell line TALL-104. Oncol. Rep. 6, 1181–1188.PubMedGoogle Scholar
  58. 58.
    Ioannides C, Fisk B, Jerome K, et al. (1993) Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J. Immunol. 151, 3693–3703.PubMedGoogle Scholar
  59. 59.
    Jerome K, Barnd D, Bendt K, et al. (1991) Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res. 51, 2908–2916.PubMedGoogle Scholar
  60. 60.
    Barnd D, Lan M, Metzgar R, et al. (1989) Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc. Natl. Acad. Sci. USA 86, 7159–7163.PubMedCrossRefGoogle Scholar
  61. 61.
    Finn O, Jerome K, Henderson R, et al. (1995) MUC1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol. Rev. 145, 61–89.PubMedCrossRefGoogle Scholar
  62. 62.
    Kotera Y, Fontenot J, Pecher G, et al. (1994) Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic and colon cancer patients. Cancer Res. 54, 2856–2860.PubMedGoogle Scholar
  63. 63.
    Xing P-X, Michael M, Apostolopoulos V, et al. (1995) Phase I study of synthetic MUC1 peptides in breast cancer. Int. J. Oncol. 6, 1283–1289.PubMedGoogle Scholar
  64. 64.
    Goydos J, Elder E, Whiteside T, et al. (1996) A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J. Surg. Res. 63, 298–304.PubMedCrossRefGoogle Scholar
  65. 65.
    Scholl SM, Balloul JM, Le Goc G, et al. (2000) Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J. Immunother. 23, 570–580.PubMedCrossRefGoogle Scholar
  66. 66.
    Itzkowitz SH, Yuan M, Montgomery CK, et al. (1989) Expression of Tn, sialosyl-Tn and T antigens in human colon cancer. Cancer Res. 49, 197–204.PubMedGoogle Scholar
  67. 67.
    Longenecker B, Reddish M, Miles D, et al. (1993) Synthetic tumor-associated sialyl-Tn antigen as an immunotherapeutic cancer vaccine. Vaccine Res. 2, 151–162.Google Scholar
  68. 68.
    Miles D, Happerfield L, Smith P, et al. (1994) Expression of sialyl-Tn predicts the utility of adjuvant chemotherapy in node positive breast cancer. Br. J. Cancer 70, 1272–1275.PubMedCrossRefGoogle Scholar
  69. 69.
    MacLean G, Miles D, Rubens R, et al. (1996) Enhancing the effect of THERATOPE Stn-KLH cancer vaccine patients with metastatic breast cancer by pre-treatment with low-dose intravenous cyclophosphamide. J. Immunother. 19, 309–316.CrossRefGoogle Scholar
  70. 70.
    Fung P, Longenecker B (1991) Specific immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine adenocarcinoma (TA3-HA). Cancer Res. 51, 1170–1176.PubMedGoogle Scholar
  71. 71.
    MacLean G, Reddish M, Koganty R, et al. (1996) Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J. Immunol. Emphasis Tumor Immunol. 19, 59–68.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Daniela Santoli
  • Sophie Visonneau

There are no affiliations available

Personalised recommendations